Laboratory-Based BiomarkersEmerging & Exploratory
Laboratory-Based Biomarkers • Exploratory Tools

Emerging and Exploratory Biomarkers

Overview of APRI, NAFLD Fibrosis Score (NFS), automated Elecsys PRO-C3 (ADAPT), OWLiver (MASEF), LIVERFASt, and upgraded NIS2+ (NASHnext).

What This Means for Patients

You may see older scores like APRI and NFS on online calculators, or newer specialized blood tests like automated Elecsys PRO-C3 (ADAPT), OWLiver (MASEF), LIVERFASt, and upgraded 2-marker NIS2+ (NASHnext) in specialty liver clinics and clinical trials. Note that commercial NASHnext at Labcorp has transitioned from the older 4-marker NIS4 panel to NIS2+ (miR-34a-5p + YKL-40, corrected for sex), removing HbA1c so changes in diabetes blood sugar no longer skew your liver score.

Biomarker / Diagnostic Type Potential Use Limitations
APRI Serum-based fibrosis score based on AST and platelet count1 Simple screening tool to determine risk of advanced fibrosis (≥F3); alternative to FIB-41 Lower accuracy in MASLD compared with other diseases1
NFS Composite score (age, BMI, AST, ALT, albumin, platelets, diabetes status)1 Simple screening tool to determine risk of advanced fibrosis (≥F3); alternative to FIB-41 Performance varies across populations (ie, BMI ranges)1
PRO-C3 (Elecsys® / ADAPT) Direct type III collagen formation neo-epitope; automated Roche Elecsys® PRO-C3 immunoassay launched 20252,3 Combined with platelet count, age, and diabetes status in the ADAPT score to stage advanced liver fibrosis (≥F3) and active fibrogenesis3 Circulating PRO-C3 can also rise in extrahepatic fibrotic or solid-tumor desmoplastic processes4
OWLiver®a Lipidomics-based blood test5 Provides up to 2 readouts: (1) classification of at-risk MASH (NAS ≥4 and ≥F2 using the MASEF score); (2) if not at-risk MASH, then likelihood of MASH vs isolated steatosis5 Requires validation in larger cohorts, with simplified methodology and cost-effectiveness data before broad clinical adoption2,5
LIVERFASt™a Multi-marker panel (A2M, haptoglobin, apolipoprotein A1, total bilirubin, GGT, ALT, AST, fasting glucose, triglycerides, cholesterol), age, sex, and BMI6 Noninvasive fibrosis and steatosis assessment6 AI algorithm of biological parameters and limited evidence that characterize test performance at prespecified thresholds7,8
NIS2+® (NASHnext®)a
Upgrades legacy 4-marker NIS4™
2-biomarker serum score combining circulating miR-34a-5p and YKL-40 with sex correction (removes A2M and whole-blood HbA1c from legacy NIS4)9,10 Identifies at-risk MASH (NAS ≥4 and F ≥2): <0.46 rules out at-risk MASH; ≥0.68 rules in at-risk MASH without glycemic HbA1c confounding (Labcorp 504960 / CPT 0468U)9,11 Proprietary algorithm;11 optimized to detect active at-risk MASH rather than stage F4 cirrhosis in isolation9,10
Several emerging biomarkers — particularly automated PRO-C3 (ADAPT) and 2-marker NIS2+ — substantially improve noninvasive detection of active fibrogenesis and at-risk MASH while formal integration into first-line society algorithms continues.